Tone mix
Week by week 50 weeks
Share of Immunovant, Inc. Common Stock's 121 headlines over the last 52 weeks by the model's call, and the same mix week by week.
Biggest swings in the last year
The weeks whose tone moved furthest from the 8-week average, with the story most outlets carried that week.
- Week of Oct 6, 2025 · tone -99JPMorgan Lowers PT on Immunovant (IMVT) to $33 From $37-124
- Week of Nov 3, 2025 · tone +100Immunovant (IMVT) Soars 14.6% Ahead of Q3 Results+100
- Week of Jun 1, 2026 · tone +100H.C. Wainwright Raises Price Target on Immunovant (IMVT) Following Positive Rheumatoid Arthritis Trial Data+71
- Week of Aug 10, 2026 · tone -66Immunovant (NASDAQ:IMVT) Releases Earnings Results, Misses Estimates By $0.12 EPS-66
- Week of Jun 22, 2026 · tone +100Immunovant's FcRn Approach Draws Analyst Upgrades After Arthritis Readout, With Armistice Capital Among Its Holders+64
- Week of Mar 2, 2026 · tone +100Immunovant, Inc. (IMVT) Analysts Raise Price Targets Following Q3 Earnings Update+61
Daily headline tone, last 90 sessions
Hover a session for its totals; click to pin.
Each point is the average score of the headlines about Immunovant, Inc. Common Stock in one trading session, with the 8-session average drawn through it. Sessions with no headline about the company have no point.
Tone by period
Show the table · 3 rows, 3 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Last 7 sessions | 0 | No headlines |
| Last 30 sessions | 12 | +8 |
| Last 90 sessions | 32 | -6 |
No matching rows. Clear the filter to see all records.
Every headline in the period counts equally.
Headlines on Friday, October 16, 2026
1 headline, average tone +85: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.clinicalleader.com · 1 outletWhy Early Device Decisions Matter How Immunovant Accelerated Its Clinical ProgramPositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Why Early Device Decisions Matter How Immunovant Accelerated Its Clinical Program | www.clinicalleader.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
Headlines on Tuesday, October 13, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.prnewswire.com · 2 outletsKuehn Law Encourages Investors of Immunovant, Inc. to Contact Law FirmNeutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm | www.prnewswire.com | 2 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Monday, October 12, 2026
2 headlines, average tone 0: 0 positive, 2 neutral and 0 negative. Showing all 2.
- www.themarketsdaily.com · 1 outletImmunovant (NASDAQ:IMVT) Insider Tuyl Christopher Van Sells 1,327 Shares of Company StockNeutral
- www.themarketsdaily.com · 1 outletImmunovant (NASDAQ:IMVT) Stock: Insider Jay Stout Sells 3,809 SharesNeutral
Show the table · 2 rows, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Immunovant (NASDAQ:IMVT) Insider Tuyl Christopher Van Sells 1,327 Shares of Company Stock | www.themarketsdaily.com | 1 | Neutral |
| Immunovant (NASDAQ:IMVT) Stock: Insider Jay Stout Sells 3,809 Shares | www.themarketsdaily.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Thursday, October 8, 2026
1 headline, average tone 0: 0 positive, 1 neutral and 0 negative. Showing all 1.
- www.themarketsdaily.com · 1 outletImmunovant (NASDAQ:IMVT) CEO Sells $119,589.66 in StockNeutral
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Immunovant (NASDAQ:IMVT) CEO Sells $119,589.66 in Stock | www.themarketsdaily.com | 1 | Neutral |
No matching rows. Clear the filter to see all records.
Headlines on Wednesday, October 7, 2026
1 headline, average tone +100: 1 positive, 0 neutral and 0 negative. Showing all 1.
- www.dailypolitical.com · 1 outletImmunovant, Inc. (NASDAQ:IMVT) Stock Rated "Moderate Buy" by Wall Street AnalystsPositive
Show the table · 1 row, 4 columns
Scroll sideways to compare all columns. Select a heading to sort.
| Immunovant, Inc. (NASDAQ:IMVT) Stock Rated "Moderate Buy" by Wall Street Analysts | www.dailypolitical.com | 1 | Positive |
No matching rows. Clear the filter to see all records.
How the score works
A headline's tone is not a forecast of the share price. Read the headlines themselves before acting on an average.
Which headlines count
Headlines come from the GDELT global news feed from 2019-09-23 on. A headline counts only when a model judges it to be about Immunovant, Inc. Common Stock, not a passing mention.
How each headline is scored
The model calls each headline positive, neutral or negative news for the company. A period's tone is the share of positive minus negative headlines, from -100 (all negative) to +100 (all positive).
When a headline counts
Headlines published by 9:15 a.m. New York time belong to that day's session. Later and weekend headlines move to the next trading session.
Repeated stories
When several outlets carry the same headline, it counts once per session.